Blood TransfusionOPTIMIZEDOACNCT07309848
Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs
An observational study of Blood Transfusion and Hip Fracture Surgeries, run by St. Antonius Hospital at 7 sites in Netherlands.
Trial summary
This study looks at patients with hip fractures who are taking direct oral anticoagulants (DOACs), a type of blood thinner. In many hospitals, surgery for these patients is delayed because of concerns about bleeding, but waiting longer can also increase risks such as complications and longer hospital stays. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Blood Transfusion, Hip Fracture Surgeries, Geriatric
- How many people
- 374 participants
- Where
- 7 sitesNetherlands
- Study dates
- 1 Nov 2025to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Study participants will be selected from patients admitted with an isolated hip fracture to one of seven Dutch level 2 trauma centers. All patients are routinely treated according to local hospital protocols, which differ in surgical timing policies for patients on direct oral anticoagulants. This natural variation provides the basis for the study cohorts (<24h vs >24h to surgery).
Who may be able to join
- Isolated hip fracture classified as AO/OTA 31A or 31B requiring surgical intervention.
- Current DOAC use with the last dose taken ≤24 hours before emergency department (ED) presentation
Who cannot join
- Pathologic or periprosthetic hip fractures.
- Fracture sustained >24 hours before ED presentation.
- Inter-hospital transfer.
- Hematologic disorders (e.g., thalassemia, sickle cell disease, aplastic anemia, myelodysplastic syndromes, leukemia).
- Use of a non-EMA-approved DOAC (e.g., betrixaban).
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
7 sites in 1 country
Netherlands7 sites, 7 recruiting
- Recruiting
Ziekenhuisgroep Twente Hospital
Almelo
Han Hegeman, MD, PhD, +31637557472, h.hegeman@zgt.nl
- Recruiting
Onze Lieve Vrouw Gasthuis Hospital
Amsterdam
Diederik Kempen, MD, PhD, +31637557472, D.H.R.Kempen@olvg.nl
- Recruiting
Rijnstate Hospital
Arnhem
Diederik Smeeing, MD, PhD, +31637557472, dsmeeing@rijnstate.nl
- Recruiting
Deventer Hospital
Deventer
Elvira Flikweert, MD, PhD, +31637557472, elviraflikweert@hotmail.com
- Recruiting
Martini Hospital
Groningen
Eelke Bosma, MD, PhD, +31637557472, eelke.bosma@mzh.nl
- Recruiting
Diakonessenhuis Hospital
Utrecht
Frans Jasper Wijdicks, MD, PhD, +31637557472, fwijdicks@diakhuis.nl
- Recruiting
St. Antonius Hospital
Utrecht
Tim Schiepers, MD, +31637557472, t.schiepers@antoniusziekenhuis.nl
Henk Schuijt, MD, PhD, +31651915397, h.j.schuijt@amsterdamumc.nl
About this study
Official title: Blood Transfusion Risk After Early vs. Delayed Surgery in Hip Fracture Patients on Direct Oral Anticoagulants: A Natural Experiment
This study looks at patients with hip fractures who are taking direct oral anticoagulants (DOACs), a type of blood thinner. In many hospitals, surgery for these patients is delayed because of concerns about bleeding, but waiting longer can also increase risks such as complications and longer hospital stays. The purpose of this study is to find out whether operating within 24 hours is as safe as delaying surgery beyond 24 hours. Specifically, the investigators want to know if early surgery does not lead to a higher need for blood transfusions compared to delayed surgery.
Read the detailed description
Detailed Description Hip fractures are one of the most common reasons for hospital admission among older adults, and surgery is usually performed as quickly as possible because delays are linked to higher risks of complications, longer hospital stays, and even increased mortality. However, in patients who are taking direct oral anticoagulants (DOACs), surgeons often postpone surgery due to concerns about bleeding. While waiting allows time for the anticoagulant effect to diminish, it also exposes patients to the risks of surgical delay.
At present, there is no clear international consensus on the safest timing for surgery in this group of patients. Some hospitals routinely wait 24-48 hours, while other hospitals have a protocol that allows to operate within 24 hours based on expert-opinion. This variation in clinical practice across hospitals in the Netherlands creates a unique opportunity to study the question as a natural experiment.
This multicenter cohort study will compare outcomes between patients who undergo hip fracture surgery within 24 hours of emergency department presentation ("early surgery") and those who undergo surgery after 24 hours ("delayed surgery"). The primary focus is whether early surgery leads to a higher risk of requiring a blood transfusion after the operation. Secondary analyses will evaluate perioperative hemoglobin changes, postoperative complications (including infections, delirium, and thromboembolic events), hospital length of stay, mortality rates, and functional recovery at three months.
Data Collection and Quality This study relies on clinical data routinely documented in the electronic health record (EHR). No additional procedures or interventions are carried out. Before the start of the study, a standardized preparation phase was implemented across all participating hospitals to ensure that every variable required for analysis would be registered consistently and completely in the EHR.
To achieve this, variables that are frequently underreported were identified, including the timing and indication of the last DOAC dose, nutritional and frailty assessments, and reasons for surgical delay, and actively addressed them in advance. Posters and concise checklists were distributed to all relevant clinical teams (emergency medicine, anesthesiology, geriatrics, surgery, and nursing) to raise awareness and provide clear reminders. By embedding these prompts into daily clinical practice, a shared understanding among staff was established that these data points are critical for the study and must be documented accurately in the patient record.
With this groundwork in place, all eligible patients are flagged locally by the principal investigator at each site. The central research team then retrospectively extracts the required information directly from the EHR.
Data Management and Quality Assurance All study data are obtained directly from the electronic health record (EHR) and subsequently transferred into a secure study database managed by the coordinating center. Prior to study initiation, a study-specific data dictionary was developed, clearly defining each variable, its source in the EHR, coding, and units of measurement.
Because all variables are documented as part of routine care, the main safeguard for data quality is the preparation phase in which clinical teams were instructed to record these variables in a standardized way. To support this, range and consistency checks (e.g., implausible hemoglobin values or mismatch between transfusion status and transfusion counts) are applied during data extraction and cleaning.
Data quality is monitored centrally through multiple checks. Completeness of the dataset is reviewed on a recurring basis, and any ambiguities are resolved in consultation with the local principal investigator. If missing or inconsistent data are detected, the hospital concerned will be informed and instructed to improve its documentation procedures to prevent further gaps. In addition, a random sample of records will undergo source data verification against the EHR to confirm accuracy.
All data management procedures follow Good Clinical Practice (GCP) principles and comply with institutional and national privacy regulations; direct identifiers remain within the local hospital, and only coded datasets are used for central analysis.
Sample Size and Rationale for Non-Inferiority This study is designed as a non-inferiority prospective cohort in the form of a natural experiment. Prior data suggest transfusion rates of ~15% after delayed surgery and ~10% after early surgery in hip fracture patients using DOACs. In consultation with clinical experts, a non-inferiority margin of 5% was set as clinically acceptable. Non-inferiority will be concluded if the upper bound of the one-sided 95% CI for the risk difference does not exceed this margin.
With an alpha of 0.05 (one-sided), 90% power, and the above event rates, 374 patients (187 per group) are required. As the calculation is based on the per-protocol population, inclusion will continue until both groups each contain 187 patients treated according to their hospital's surgical timing protocol (<24h in early-surgery centers, >24h in delayed-surgery centers). Because intention-to-treat (ITT) analyses include all eligible patients by hospital policy regardless of actual timing, the ITT population is expected to exceed 374. No loss to follow-up is anticipated, as the primary outcome is assessed during hospitalization.
Statistical Analysis The primary outcome is the requirement for postoperative blood transfusion (yes/no). Non-inferiority will be tested by calculating the absolute risk difference between groups with a one-sided 95% CI. A multivariable logistic regression will also be performed to estimate the odds ratio (OR) for transfusion, adjusting for confounders including age, sex, DOAC type, and surgical procedure. With an expected 56 events, inclusion of up to five covariates is feasible without overfitting.
The primary analysis will follow the per-protocol principle, excluding patients whose actual surgical timing deviated from their hospital's standard policy. An additional ITT analysis will be conducted to preserve the quasi-randomization of the natural experiment and test robustness. Inter-hospital variability will be assessed using the intraclass correlation coefficient; if clustering is present, multilevel logistic regression will be applied.
Secondary Outcomes Secondary outcomes will be analyzed according to their measurement scale and distribution. Continuous variables, such as hemoglobin drop, bleeding index, and hospital length of stay, will first be tested for normality and analyzed with t-tests if normally distributed or Mann-Whitney U tests if not. Ordinal or categorical variables with more than two categories, such as the number of transfusion units, will be compared using Chi-square tests. Binary outcomes, including postoperative complications, thromboembolic events, and hemoglobin drop >2 mmol/L, will be analyzed using Chi-square tests or Fisher's exact test if cell counts are small.
Handling of Missing Data The investigators do not anticipate substantial missing data, given the extensive preparatory work undertaken to ensure consistent documentation across all participating hospitals. However, if missing values do occur, they will first be examined for patterns and mechanisms (missing completely at random, at random, or not at random). Where appropriate, multiple imputation by chained equations (MICE) will be applied to account for missing values in key variables. Extreme or implausible values will be flagged and verified against the EHR; if they cannot be corrected, they will be treated as missing.
Expected Impact If early surgery proves to be as safe as delayed surgery, the results of this study could support more uniform and evidence-based guidelines. This may reduce unnecessary delays in surgery, improve outcomes, shorten hospital stays, and enhance recovery for thousands of older patients worldwide who sustain a hip fracture while using DOACs.
- Conditions
- Blood Transfusion, Hip Fracture Surgeries, Geriatric, Bleeding Complications, Bleeding as Surgical Complication (Treatment), Bleeding
- Keywords
- natural experiment, doac, direct oral anticoagulant, hip fracture, geriatric, surgery, bleeding, blood transfusion, early, delayed
- Medical subject headings
- Hemorrhage, Transfusion Reaction, Hip Fractures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Early surgery | Surgery within 24 hours after last DOAC intake | |
| Delayed surgery | Surgery after more than 24 hours after last DOAC intake |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants receiving a postoperative blood transfusion
Receiving one or more units of packed red blood cells in the postoperative period during hospitalization
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Secondary outcomes (36)
Number of participants receiving a preoperative blood transfusion
Any administration of one or more units of packed red blood cells before hip fracture surgery during hospitalization.
Measured: From emergency department presentation until start of surgery (up to 7 days preoperatively)
Number of packed red blood cells administered postoperatively
Total number of packed red blood cell units administered after hip fracture surgery during hospitalization.
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of packed red blood cells administered preoperatively
Total number of packed red blood cell units administered before hip fracture surgery during hospitalization.
Measured: From emergency department presentation until start of surgery (up to 7 days preoperatively)
Surgical duration in minutes
Measured: During surgery/procedure
Intraoperative blood loss in milliliteres
Measured: During surgery
Number of participants requiring intraoperative use of tranexamic acid, fibrinogen or trombocytes
Measured: During surgery
Number of participants requiring a reoperation
Measured: From end of surgery until hospital discharge
Number of participants categorized by reason for reoperation
Classification of the clinical reason for an unplanned reoperation after hip fracture surgery. Reasons will be categorized as:
postoperative bleeding postoperative infection wound complications implant-related complications other specified causes
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with postoperative sciatic neuropraxia
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Postoperative hemoglobin
Measured: Measured within 24 hours postoperatively
Postoperative hematocrite
Measured: Measured within 24 hours postoperatively
Delta hemoglobin
Calculated as the difference between preoperative and postoperative hemoglobin
Measured: Measured within 24 hours postoperatively
Bleeding index
Calculated as the difference between preoperative and postoperative hemoglobin plus the amount of packed red blood cells administered
Measured: Measured within 24 hours postoperatively
Number of participants with a hemoglobin change greater than 2 mmol/L
Hemoglobin change of more than 2 millimol/liter
Measured: Measured within 24 hours postoperatively
Number of participants with postoperative anemia
Defined as hemoglobin <8.5 mmol/L in males or <7.5 mmol/L in females within 24 hours postoperatively
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with postoperative hematoma
Diagnosed by attending physician
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Time untill restart of DOAC
Time between last DOAC intake and restart of DOAC
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a myocardial infarction
Confirmed on electro cardio gram (ECG)
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with arterial thrombosis
Diagnosed by attending physician
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of particiapants with a deep venous thrombosis
Diagnosed with ultrasound
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a pulmonary embolism
CTA confirmed
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a pressure ulcer
Diagnosed by attending physician
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a delirium
Diagnosed by either geriatrician or physician assistant of the consultative orthogeriatric trauma team
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a pneumonia
Confirmed by chest radiograph or positive sputum culture
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a superficial surgical wound infection
Diagnosed by attending physician
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a deep surgical wound infection
Diagnosed by attending physician
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with wound leakage
Diagnosed by attending physician
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Days of wound leakage
Diagnosed by attending physician
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with congestive heart failure
Diagnosed by attending physician
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with renal insufficiency
More than 24ml/min decrease in glomerular filtration rate (GFR) compared to GFR at admission
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a urinary tract infection
Positive urine culture
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with an in hospital fall
Any fall
Measured: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with in-hospital mortality
Death during hospitalization
Measured: From end of hip fracture surgery until hospital discharge (up to 120 days postoperatively)
Number of participants with a 30-day mortality
Death within 30 days after hip fracture surgery
Measured: 30 days after hip fracture surgery
Hospital length of stay
In days
Measured: Day of Emergency Department presentation until day of hospital discharge
Discharge destination
Place to which the patient is discharged after admission
Measured: At the day of hospital discharge after hip facture surgery (up to 120 days postoperatively)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Dec 2025
- Study start1 Nov 2025
- Primary completion1 Sep 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Blood TransfusionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 374 participants (estimated)
Sponsor and investigators
- Lead sponsor
- St. Antonius Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tim Schiepers, St. Antonius Hospital
- Investigators
- Henk Jan Schuijt, MD, PhD, Principal investigator, Amsterdam University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07309848
- Sponsor's protocol ID
- W25.034
- Acronym
- OPTIMIZEDOAC
- Status last verified
- Dec 2025
- First submitted
- 22 Sep 2025
- Last updated
- 30 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD) underlying the primary and secondary analyses will be shared, including baseline demographics, comorbidities, frailty and nutritional scores, laboratory values, fracture and surgical details, perioperative medication use, and postoperative outcomes such as transfusion status, complications, length of stay, and mortality. A data dictionary with definitions, coding, and units for each variable will also be provided. Data will become available after publication of the primary results and may be obtained upon reasonable request from qualified researchers. Requests must include a methodologically sound proposal and will require approval by the study steering committee. Access will be granted only after signing a data sharing agreement to ensure appropriate use and compliance with privacy regulations, and requests can be submitted to the coordinating investigator at St. Antonius Hospital, Utrecht.
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Blood Transfusion Risk After Early vs. Delayed Surgery in Hip Fracture Patients on Direct Oral Anticoagulants: A Natural Experiment
- ClinicalTrials.gov ID
- NCT07309848
- Acronym / sponsor ID
- OPTIMIZEDOAC / W25.034
- Conditions
- Blood Transfusion, Hip Fracture Surgeries, Geriatric, Bleeding Complications, Bleeding as Surgical Complication (Treatment), Bleeding
- Keywords
- natural experiment, doac, direct oral anticoagulant, hip fracture, geriatric, surgery, bleeding, blood transfusion
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 374 participants (estimated)
- Lead sponsor
- St. Antonius HospitalUniversity, hospital or other
- Study start
- 1 Nov 2025 (actual)
- Primary completion
- 1 Sep 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 30 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study looks at patients with hip fractures who are taking direct oral anticoagulants (DOACs), a type of blood thinner. In many hospitals, surgery for these patients is delayed because of concerns about bleeding, but waiting longer can also increase risks such as complications and longer hospital stays. The purpose of this study is to find out whether operating within 24 hours is as safe as delaying surgery beyond 24 hours. Specifically, the investigators want to know if early surgery does not lead to a higher need for blood transfusions compared to delayed surgery.
Detailed description
Detailed Description Hip fractures are one of the most common reasons for hospital admission among older adults, and surgery is usually performed as quickly as possible because delays are linked to higher risks of complications, longer hospital stays, and even increased mortality. However, in patients who are taking direct oral anticoagulants (DOACs), surgeons often postpone surgery due to concerns about bleeding. While waiting allows time for the anticoagulant effect to diminish, it also exposes patients to the risks of surgical delay.
At present, there is no clear international consensus on the safest timing for surgery in this group of patients. Some hospitals routinely wait 24-48 hours, while other hospitals have a protocol that allows to operate within 24 hours based on expert-opinion. This variation in clinical practice across hospitals in the Netherlands creates a unique opportunity to study the question as a natural experiment.
This multicenter cohort study will compare outcomes between patients who undergo hip fracture surgery within 24 hours of emergency department presentation ("early surgery") and those who undergo surgery after 24 hours ("delayed surgery"). The primary focus is whether early surgery leads to a higher risk of requiring a blood transfusion after the operation. Secondary analyses will evaluate perioperative hemoglobin changes, postoperative complications (including infections, delirium, and thromboembolic events), hospital length of stay, mortality rates, and functional recovery at three months.
Data Collection and Quality This study relies on clinical data routinely documented in the electronic health record (EHR). No additional procedures or interventions are carried out. Before the start of the study, a standardized preparation phase was implemented across all participating hospitals to ensure that every variable required for analysis would be registered consistently and completely in the EHR.
To achieve this, variables that are frequently underreported were identified, including the timing and indication of the last DOAC dose, nutritional and frailty assessments, and reasons for surgical delay, and actively addressed them in advance. Posters and concise checklists were distributed to all relevant clinical teams (emergency medicine, anesthesiology, geriatrics, surgery, and nursing) to raise awareness and provide clear reminders. By embedding these prompts into daily clinical practice, a shared understanding among staff was established that these data points are critical for the study and must be documented accurately in the patient record.
With this groundwork in place, all eligible patients are flagged locally by the principal investigator at each site. The central research team then retrospectively extracts the required information directly from the EHR.
Data Management and Quality Assurance All study data are obtained directly from the electronic health record (EHR) and subsequently transferred into a secure study database managed by the coordinating center. Prior to study initiation, a study-specific data dictionary was developed, clearly defining each variable, its source in the EHR, coding, and units of measurement.
Because all variables are documented as part of routine care, the main safeguard for data quality is the preparation phase in which clinical teams were instructed to record these variables in a standardized way. To support this, range and consistency checks (e.g., implausible hemoglobin values or mismatch between transfusion status and transfusion counts) are applied during data extraction and cleaning.
Data quality is monitored centrally through multiple checks. Completeness of the dataset is reviewed on a recurring basis, and any ambiguities are resolved in consultation with the local principal investigator. If missing or inconsistent data are detected, the hospital concerned will be informed and instructed to improve its documentation procedures to prevent further gaps. In addition, a random sample of records will undergo source data verification against the EHR to confirm accuracy.
All data management procedures follow Good Clinical Practice (GCP) principles and comply with institutional and national privacy regulations; direct identifiers remain within the local hospital, and only coded datasets are used for central analysis.
Sample Size and Rationale for Non-Inferiority This study is designed as a non-inferiority prospective cohort in the form of a natural experiment. Prior data suggest transfusion rates of ~15% after delayed surgery and ~10% after early surgery in hip fracture patients using DOACs. In consultation with clinical experts, a non-inferiority margin of 5% was set as clinically acceptable. Non-inferiority will be concluded if the upper bound of the one-sided 95% CI for the risk difference does not exceed this margin.
With an alpha of 0.05 (one-sided), 90% power, and the above event rates, 374 patients (187 per group) are required. As the calculation is based on the per-protocol population, inclusion will continue until both groups each contain 187 patients treated according to their hospital's surgical timing protocol (<24h in early-surgery centers, >24h in delayed-surgery centers). Because intention-to-treat (ITT) analyses include all eligible patients by hospital policy regardless of actual timing, the ITT population is expected to exceed 374. No loss to follow-up is anticipated, as the primary outcome is assessed during hospitalization.
Statistical Analysis The primary outcome is the requirement for postoperative blood transfusion (yes/no). Non-inferiority will be tested by calculating the absolute risk difference between groups with a one-sided 95% CI. A multivariable logistic regression will also be performed to estimate the odds ratio (OR) for transfusion, adjusting for confounders including age, sex, DOAC type, and surgical procedure. With an expected 56 events, inclusion of up to five covariates is feasible without overfitting.
The primary analysis will follow the per-protocol principle, excluding patients whose actual surgical timing deviated from their hospital's standard policy. An additional ITT analysis will be conducted to preserve the quasi-randomization of the natural experiment and test robustness. Inter-hospital variability will be assessed using the intraclass correlation coefficient; if clustering is present, multilevel logistic regression will be applied.
Secondary Outcomes Secondary outcomes will be analyzed according to their measurement scale and distribution. Continuous variables, such as hemoglobin drop, bleeding index, and hospital length of stay, will first be tested for normality and analyzed with t-tests if normally distributed or Mann-Whitney U tests if not. Ordinal or categorical variables with more than two categories, such as the number of transfusion units, will be compared using Chi-square tests. Binary outcomes, including postoperative complications, thromboembolic events, and hemoglobin drop >2 mmol/L, will be analyzed using Chi-square tests or Fisher's exact test if cell counts are small.
Handling of Missing Data The investigators do not anticipate substantial missing data, given the extensive preparatory work undertaken to ensure consistent documentation across all participating hospitals. However, if missing values do occur, they will first be examined for patterns and mechanisms (missing completely at random, at random, or not at random). Where appropriate, multiple imputation by chained equations (MICE) will be applied to account for missing values in key variables. Extreme or implausible values will be flagged and verified against the EHR; if they cannot be corrected, they will be treated as missing.
Expected Impact If early surgery proves to be as safe as delayed surgery, the results of this study could support more uniform and evidence-based guidelines. This may reduce unnecessary delays in surgery, improve outcomes, shorten hospital stays, and enhance recovery for thousands of older patients worldwide who sustain a hip fracture while using DOACs.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Early surgery | – | –Surgery within 24 hours after last DOAC intake |
| Delayed surgery | – | –Surgery after more than 24 hours after last DOAC intake |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Study participants will be selected from patients admitted with an isolated hip fracture to one of seven Dutch level 2 trauma centers. All patients are routinely treated according to local hospital protocols, which differ in surgical timing policies for patients on direct oral anticoagulants. This natural variation provides the basis for the study cohorts (<24h vs >24h to surgery).
Key inclusion criteria (2 listed)
- Isolated hip fracture classified as AO/OTA 31A or 31B requiring surgical intervention.
- Current DOAC use with the last dose taken ≤24 hours before emergency department (ED) presentation
Key exclusion criteria (5 listed)
- Pathologic or periprosthetic hip fractures.
- Fracture sustained >24 hours before ED presentation.
- Inter-hospital transfer.
- Hematologic disorders (e.g., thalassemia, sickle cell disease, aplastic anemia, myelodysplastic syndromes, leukemia).
- Use of a non-EMA-approved DOAC (e.g., betrixaban).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of participants receiving a postoperative blood transfusion
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Receiving one or more units of packed red blood cells in the postoperative period during hospitalization
36 secondary outcomes
Number of participants receiving a preoperative blood transfusion
Time frame: From emergency department presentation until start of surgery (up to 7 days preoperatively)
Number of packed red blood cells administered postoperatively
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of packed red blood cells administered preoperatively
Time frame: From emergency department presentation until start of surgery (up to 7 days preoperatively)
Surgical duration in minutes
Time frame: During surgery/procedure
Intraoperative blood loss in milliliteres
Time frame: During surgery
Number of participants requiring intraoperative use of tranexamic acid, fibrinogen or trombocytes
Time frame: During surgery
Number of participants requiring a reoperation
Time frame: From end of surgery until hospital discharge
Number of participants categorized by reason for reoperation
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with postoperative sciatic neuropraxia
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Postoperative hemoglobin
Time frame: Measured within 24 hours postoperatively
Postoperative hematocrite
Time frame: Measured within 24 hours postoperatively
Delta hemoglobin
Time frame: Measured within 24 hours postoperatively
Bleeding index
Time frame: Measured within 24 hours postoperatively
Number of participants with a hemoglobin change greater than 2 mmol/L
Time frame: Measured within 24 hours postoperatively
Number of participants with postoperative anemia
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with postoperative hematoma
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Time untill restart of DOAC
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a myocardial infarction
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with arterial thrombosis
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of particiapants with a deep venous thrombosis
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a pulmonary embolism
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a pressure ulcer
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a delirium
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a pneumonia
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a superficial surgical wound infection
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a deep surgical wound infection
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with wound leakage
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Days of wound leakage
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with congestive heart failure
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with renal insufficiency
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with a urinary tract infection
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with an in hospital fall
Time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)
Number of participants with in-hospital mortality
Time frame: From end of hip fracture surgery until hospital discharge (up to 120 days postoperatively)
Number of participants with a 30-day mortality
Time frame: 30 days after hip fracture surgery
Hospital length of stay
Time frame: Day of Emergency Department presentation until day of hospital discharge
Discharge destination
Time frame: At the day of hospital discharge after hip facture surgery (up to 120 days postoperatively)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2025.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD) underlying the primary and secondary analyses will be shared, including baseline demographics, comorbidities, frailty and nutritional scores, laboratory values, fracture and surgical details, perioperative medication use, and postoperative outcomes such as transfusion status, complications, length of stay, and mortality. A data dictionary with definitions, coding, and units for each variable will also be provided. Data will become available after publication of the primary results and may be obtained upon reasonable request from qualified researchers. Requests must include a methodologically sound proposal and will require approval by the study steering committee. Access will be granted only after signing a data sharing agreement to ensure appropriate use and compliance with privacy regulations, and requests can be submitted to the coordinating investigator at St. Antonius Hospital, Utrecht.
Related trials for Blood Transfusion
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
RecruitingPhase 3
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Myelodysplastic Syndromes
RecruitingPhase 3
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
Myelodysplastic Syndrome, Anemia
Active, not recruiting
Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.
Transfusion-dependent Beta-Thalassemia
RecruitingPhase 1/2
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
Bone Marrow Failure Syndromes, Aplastic Anemias
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Henk Jan Schuijt, MD, PhD principal investigator
Amsterdam University Medical Center
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Blood Transfusion and Hip Fracture Surgeries, run by St. Antonius Hospital at 7 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tim Schiepers, MD (+31637557472, t.schiepers@antoniusziekenhuis.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants receiving a postoperative blood transfusion (time frame: From end of hip fracture surgery until hospital discharge (up to 30 days postoperatively)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2025.